Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy [PDF]
International Journal of Women's Health, 2016 Santiago Palacios,1 María Jesús Cancelo2 1Palacios Institute of Women’s Health, Madrid, Spain; 2Gynecology and Obstetrics Department, Guadalajara University Hospital, University of Alcalá, Spain Abstract: The physiological ...
Santiago Palacios, Maria Jesus Cancelo
exaly +4 more sources
Ospemifene for vulvar and vaginal atrophy: an overview [PDF]
Drugs in Context, 2020 The menopause-related decline in estrogen levels leads to an array of genital, sexual, and urinary symptoms collectively known as genitourinary syndrome of menopause. The constellation of symptoms associated with vulvar and vaginal atrophy (VVA) can have
Santiago Palacios
doaj +2 more sources
Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies [PDF]
Drugs in Context, 2020 Women with breast cancer are at a higher risk of developing vulvar and vaginal atrophy (VVA), a major component of the genitourinary syndrome of menopause, due to the combined estrogen-depleting effects of chemotherapy, adjuvant hormone therapy, and ...
Mariella Lilue +2 more
doaj +2 more sources
Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies [PDF]
Drugs in Context, 2020 The pathophysiological changes associated with hypoestrogenism of menopause, a condition known as genitourinary syndrome of menopause, are responsible for the hallmark symptoms of vulvovaginal atrophy (VVA), namely dyspareunia secondary to vaginal ...
Ana Rosa Jurado López +1 more
doaj +2 more sources
Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies [PDF]
Drugs in Context, 2020 Pelvic floor muscle atrophy and collagen loss in connective tissue due to declining estrogen production in women as they age may underlie the increasing prevalence of urge and stress incontinence.
Zuramis Estrada Blanco +2 more
doaj +2 more sources
Experience with ospemifene in patients with vulvar and vaginal atrophy: case studies with bone marker profiles [PDF]
Drugs in Context, 2020 Selective estrogen receptor modulators (SERMs) exhibit varying agonist/antagonist activities on estrogen receptors in tissues, although most SERMs, including ospemifene, have agonist effects on bone.
María del Carmen Pingarrón Santofimia +3 more
doaj +2 more sources
Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use [PDF]
Patient Preference and Adherence, 2020 Angelo Cagnacci, 1 Anjeza Xholli, 2 Martina Venier 2 1Obstetrics and Gynaecology Unit, Obstetrics and Gynaecology University of Genova, Genova, Italy; 2Obstetrics and Gynaecology Unit, Azienda Sanitaria Universitaria Integrata di Udine, Udine ...
Cagnacci A, Xholli A, Venier M
doaj +2 more sources
Long-term effects of ospemifene on densitometric and bone metabolism biomarkers in postmenopausal women reporting Vulvar and Vaginal Atrophy (VVA) [PDF]
BMC Women's HealthOspemifene (OSP), a Selective Estrogen Receptor Modulator (SERM), is recommended for treating vulvovaginal atrophy (VVA) in postmenopausal women (PMW). Previous 12 mm data suggested that OSP therapy had beneficial effects on bone mineral and biochemical ...
Silvia Maffei +3 more
doaj +2 more sources
Vulvar and Vaginal Graft-Versus-Host Disease: prevalence and repercussions on vaginal microbiota [PDF]
Revista Brasileira de Ginecologia e ObstetríciaObjective: Allogeneic bone marrow transplantation (BMT) carries the risk of the donor's cells recognizing the recipient as abnormal, triggering Graft Versus Host Disease (GVHD).
Luiza de Amorim de Carvalho Araújo +4 more
doaj +2 more sources
Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy [PDF]
Climacteric, 2016 Rossella E Nappi +2 more
exaly +2 more sources